Evidence map›Paper›PMID 40610391›Full record

ArticleMolecular pharmaceutics2025

Utilizing Monocarboxylate Transporter 1-Mediated Blood-Brain Barrier Penetration for Glioblastoma Positron Emission Tomography Imaging with 6-[

Pyry Dillemuth, Abiodun Ayo, Tomi T Airenne, Petter Lövdahl, Emel Bakay, Xiaoqing Zhuang, Heidi Liljenbäck, Sami Tuomas Paunonen, Jonne Kunnas, Pauliina Filppu and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. [ACS omega · 2026
    Article
  4. Rapid cleavage of 6-[EJNMMI radiopharmacy and chemistry · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Pyry DillemuthTurku PET Centre, University of Turku, Turku FI-20520, Finland.
Abiodun AyoTranslational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, Helsinki FI-00290, Finland.
Tomi T AirenneStructural Bioinformatics Laboratory and InFLAMES Research Flagship Center, Biochemistry, Faculty of Science and Engineering, Åbo Akademi University, Turku FI-20520, Finland.
Petter LövdahlTurku PET Centre, University of Turku, Turku FI-20520, Finland.
Emel BakayTurku PET Centre, University of Turku, Turku FI-20520, Finland.
Xiaoqing ZhuangTurku PET Centre, University of Turku, Turku FI-20520, Finland.
Heidi LiljenbäckTurku PET Centre, University of Turku, Turku FI-20520, Finland.ORCID 0000-0001-9372-1584
Sami Tuomas PaunonenTurku PET Centre, University of Turku, Turku FI-20520, Finland.ORCID 0009-0003-4683-7850
Jonne KunnasTurku PET Centre, University of Turku, Turku FI-20520, Finland.
Pauliina FilppuTranslational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, Helsinki FI-00290, Finland.
Johan RajanderTurku PET Centre, University of Turku, Turku FI-20520, Finland.ORCID 0000-0003-3591-0963
Mark S JohnsonStructural Bioinformatics Laboratory and InFLAMES Research Flagship Center, Biochemistry, Faculty of Science and Engineering, Åbo Akademi University, Turku FI-20520, Finland.
Anne RoivainenTurku PET Centre, University of Turku, Turku FI-20520, Finland.
Tiina A SalminenStructural Bioinformatics Laboratory and InFLAMES Research Flagship Center, Biochemistry, Faculty of Science and Engineering, Åbo Akademi University, Turku FI-20520, Finland.ORCID 0000-0002-4135-8020
Jessica M RosenholmPharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, Turku FI-20520, Finland.ORCID 0000-0001-6085-1112
Pirjo LaakkonenTranslational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, Helsinki FI-00290, Finland.ORCID 0000-0002-9620-095X
Xiang-Guo LiTurku PET Centre, University of Turku, Turku FI-20520, Finland.ORCID 0000-0002-9118-7223

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma is the most malignant brain tumor in adults, and its prognosis remains dismal. The blood-brain barrier impedes the effectiveness of many drugs, which are otherwise effective for cancer treatment. Monocarboxylate transporter 1 (MCT1) is expressed on endothelial and glioblastoma cells. Our approach aims to leverage MCT1 to transport theranostic agents across the blood-brain barrier. In this context, we present herein the application of fluorine-18-labeled nicotinic acid (denoted as [

Indexed as

Blood-Brain BarrierBrain NeoplasmsFluorine RadioisotopesGlioblastomaMonocarboxylic Acid TransportersNiacinPositron-Emission TomographySymportersAnimalsCell Line, TumorFemaleHumansMiceMice, NudeMonocarboxylate Transport Protein 1RadiopharmaceuticalsFluorine-18Fluorine RadioisotopesMonocarboxylate Transport Protein 1Monocarboxylic Acid TransportersNiacinRadiopharmaceuticalsSymportersfluorine-18glioblastomaG protein-coupled receptor GPR109Amonocarboxylate transporter 1niacinnicotinic acid

Identifiers

PMID40610391
PMCPMC12326355

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.